In humans, advanced mast cell (MC) neoplasms are rare malignancies with a poor prognosis.
| INTRODUCTION
Mast cell (MC) neoplasms are haematopoietic disorders characterized by uncontrolled expansion and accumulation of neoplastic mast cells (MCs) in various organ systems. [1] [2] [3] [4] [5] [6] [7] In humans, the most frequently affected organs in systemic mastocytosis (SM) are the skin, bone marrow (BM), liver and spleen. Both indolent and aggressive variants of SM have been described. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In the canine system, cutaneous MC tumours (MCTs) are frequently detected and can be divided into less aggressive and more aggressive variants. The aggressive MCT can involve regional lymph nodes and/or visceral organs. [5] [6] [7] 14 It is worth noting that MCTs in dogs are the most frequent malignant skin tumours. [5] [6] [7] Whereas histological low-grade MCTs have a good-to-excellent prognosis, metastasized and/or high-grade canine MCTs have a poor prognosis with short STs. [5] [6] [7] In dogs as well as in humans, it is of considerable importance to establish the correct diagnosis and to define whether the patient has an indolent MC neoplasm or an advanced category of the disease.
During the past few decades, the pathogenesis and molecular mechanisms underlying disease evolution and progression of SM have been analysed. In both species, neoplastic MCs display activating KIT mutations that are considered to contribute to disease evolution. [1] [2] [3] [4] [15] [16] [17] [18] [19] [20] Based on this concept, various tyrosine kinase inhibitors (TKI) directed against KIT have been developed with the hope that these agents can act as disease-modifying drugs. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Unfortunately, clinical responses are unpredictable and often transient in both species, which remains a clinical challenge in daily practice. [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Therefore, current efforts focus on deciphering other molecular pathways involved in the pathogenesis of SM in order to establish new treatment strategies.
Comparative oncology is an emerging field that is based on the assumption that the biochemical processes and pathogenesis contributing to the evolution and progression of spontaneous malignancies in human and animal species are often comparable and that these similarities can be exploited in basic and translational science. [41] [42] [43] [44] Based on this assumption, many different projects in the field of comparative oncology have been initiated. [44] [45] [46] One emerging example with future potential might be research on human and canine MC neoplasms. 47, 48 As mentioned before, these neoplasms have several aspects in common, such as KIT mutations and a poor outcome in advanced stages.
There is hope that the field of comparative oncology can assist in (Figure 1 ).
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While the diagnosis of canine MCT can be made by a fine-needle aspiration-based cytology in a majority of the cases, histological grad- In veterinary oncology, the most frequent clinical presentation of MC neoplasms in dogs is a solitary cutaneous nodule ( Figure 1 ).
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MCTs can have a very heterogeneous appearance, not always accompanied by a positive Darier's sign, and the diagnosis of MCT can usually be established by a cytological examination of a fine-needle aspiration. [5] [6] [7] However, fine-needle biopsy-derived cytology is not sufficient to determine the grade of the MCT. Therefore, an additional histological examination of the lesion is mandatory to determine the grade of the disease and thus to anticipate the behavior of the MCT in dogs. A number of clinical, molecular, and histopathological variables are considered to be of prognostic significance in canine MCTs (Table S1 ). The first grading system was established by Patnaik et al 57 in 1984 (Table S2 ). This classification system divides canine cutaneous
MCTs into three grades, namely, grade 1 with well-differentiated morphology, grade 2 with intermediately differentiated cells, and grade 3 with poorly differentiated MCs. 57 Although this grading system correlates with the clinical outcome of patients, its practical application showed some inconsistencies because of inter-observer variations. 58, 62, 63 Therefore, a 2-tier histopathological grading system has been proposed by Kiupel et al 58 in 2011 (Table S3) , with the aim to improve the Patnaik system regarding prognostication of patients.
Nonetheless, it has been shown that approximately 15% to 20% of dogs with Kiupel low-grade MCTs have metastatic disease at presentation, 64 suggesting that there is still a need for better prognostication and an improved grading system in cutaneous MCTs, and for the moment, many centres are using both the Patnaik and Kiupel prognostication model in individual canine MCT patients. In the future, a refined prognostic grading system that includes laboratory and molecular parameters may be developed in canine MCTs.
Whether KIT mutations and/or elevated tryptase levels are of prognostic significance in canine MCTs, remains at present unknown.
| DETECTION OF KIT EXPRESSION AND EVALUATION OF THE KIT MUTATIONAL STATUS
In the human system, KIT is employed as a surface marker to detect normal and neoplastic MCs (KIT+/CD34-) by flow cytometry. 2, 8, [49] [50] [51] [52] 61 In addition, KIT is employed together with tryptase to detect and enumerate neoplastic MCs in the BM of patients with SM by immunohistochemistry. 65, 66 In adult patients with SM, the activating KIT mutation D816V is detected in a vast majority of cases.
Using highly sensitive polymerase chain reaction techniques, KIT D816V can be detected in the BM and in the peripheral blood of most adult human patients with SM. [67] [68] [69] Therefore, KIT D816V not only serves as a disease-related criterion but can also be employed as a PB screening biomarker for patients with suspected SM. 67 However, in a smaller subset of patients with SM, other KIT mutations (in codons other than 816) or no KIT mutations are found. 62 In these patients, sequencing studies of the whole KIT structure are sometimes recommended. 67 However, these studies are laborious and therefore are not regarded as standard practice.
In dogs, immunohistochemical staining for KIT is of prognostic value, as different staining patterns correlate with recurrence-rate and 51, 61 a Minimal criteria to diagnose SM (SM criteria) are shown in Table 3 . b B-findings and C-findings are listed in Table 3 Standard immunohistochemical markers applied for the detection and enumeration of MCs in the BM (or other organs) are KIT (CD117) and tryptase ( Figure 1 ). Other organ systems are usually not examined by histological studies, unless the aetiology of organopathy/organomegaly remains uncertain or the patient is suffering from a sarcoma-like disease (MC sarcoma). However, in all patients, the size of the liver and spleen is determined by ultrasound or computed tomography (CT). 61 In addition, the sizes of the involved lymph nodes, when enlarged, are measured by ultrasound and/or CT. Bone involvement with osteopenia or osteoporosis should be determined by osteodensitometry in all cases with SM. 61 Osteopenia is quite frequently detected in human patients with SM, and if not treated appropriately most of these patients progress to osteoporosis that may be complicated by pathologic bone fractures. 
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In the canine system, clinical staging includes a complete blood count with differential counts, serum chemistry and cytological or histological and immunohistochemical studies of the primary organ site and of the secondary (cutaneous or extracutaneous, metastatic) lesion(s) (Figure 1) . 57, 58 Fine-needle aspiration biopsies of regional lymph nodes (even if normal in size), abdominal ultrasound (with or without fine-needle aspiration of liver and spleen regardless of the sonographic appearance) and thoracic radiography are usually performed. 64, 73 In the majority of dogs, MCTs disseminate first into the regional lymph nodes, then to the spleen and liver, and finally into other visceral organs, whereas lung involvement is rare. 74 In a In SM patients in whom less than two B-findings and no C-finding are detected (category A), the diagnosis indolent SM can be established. When two or more B-findings but no C-findings are present, the diagnosis is smouldering SM; and when 1 or more C-findings (+/− B-findings) are detected, the final diagnosis is either aggressive SM (<20% MCs in BM smears) or MC leukaemia (MCs ≥20% on marrow smears) (see also Table 1B ).
staging (investigations of BM, blood and/or other organs), and/or prognostication of canine MCTs remain to be determined in future studies.
| UTILITY OF TRYPTASE AND OTHER DISEASE PARAMETERS DURING FOLLOW-UP
In the human system, the basal serum tryptase level is a robust and widely used follow-up parameter for patients with SM. [77] [78] [79] [80] In particular, tryptase is a serine protease that is produced and stored almost exclusively in MCs and is secreted from resting MCs into plasma in a constitutive manner. 81, 82 As a result, the basal serum tryptase level reflects the total body burden of MCs in healthy individuals (normal physiologic baseline: 1-15 ng/mL) and in patients with mastocytosis. 82 In contrast, patients with CM generally have basal serum tryptase levels within the normal range, clearly elevated tryptase levels (>20 ng/mL) are almost invariably found in patients with SM and therefore also serve as a minor diagnostic criterion of SM. 49 In addition, the tryptase level is an important follow-up parameter in SM. 61 Likewise, whereas patients with ISM have stable tryptase levels, a steadily increasing basal serum tryptase is indicative of advanced SM and/or disease progression. Furthermore, effective therapy is usually accompanied by a decrease in the serum tryptase level. 31, [35] [36] [37] 83 In addition, blood counts and (other) serum chemistry parameters, such as alkaline phosphatase levels, are employed in the follow-up of human patients with SM. 61 Furthermore, liver and spleen size (by ultrasound), lymph nodes, and the osteodensitometry (T score) are measured routinely in the follow-up of patients with SM. 61 In dogs, physical examination, in particular investigating the initial location(s) of the MCTs and regional lymph nodes, determination of blood counts and serum chemistry parameters, and abdominal ultrasound, are standard in the follow-up of MCT patients. 75 At present, no MC-specific serum-or plasma markers are available that could be employed as follow-up parameters for dogs with MCTs. Whether the inclusion of serologic MC-related follow-up parameters (like serum tryptase) would be of value for determining the course of canine MCT and for evaluation of responses to conventional or novel therapies remains to be determined in future studies.
| Treatment of Advanced SM and selection of anti-neoplastic drugs
In human patients with advanced MC neoplasm with slow progression, interferon-alpha (IFN-A) or cladribine (2CdA) have been considered as first-line therapy with response rates ranging between 10%
and 30%. [83] [84] [85] [86] In patients with rapidly progressing ASM and MCL, more intensive therapy is required. In patients who are fit and eligible, polychemotherapy containing fludarabine or 2CdA, often in combination with cytosine arabinoside (ARA-C), are recommended, and in case of a sufficient response (clear cytoreduction), haematopoietic stemcell transplantation (SCT) should be considered. 37, 49, 87, 88 In patients with poor performance status, 2CdA or hydroxyurea can be used as palliate drugs. A more recent approach is to apply targeted drugs directed against KIT D816V. 34-37 Midostaurin has recently been described to exert major disease-modifying activity in patients with advanced SM including MCL. 35, 37 In addition, midostaurin is useful for cytoreducing tumour load in patients with advanced SM prior to SCT. 37 In patients with MC sarcoma, the treatment recommendation is similar to that in MCL because most of these patients transform to ASM or MCL within weeks or months. 37, 49, 87 In addition to chemotherapy, radiation therapy may be applied in MCS patients. 37, 49, 87 However, most patients with MCS die within a short time-interval despite intensive therapy.
In dogs with resectable MCTs without distant metastasis, surgical intervention is the first-line therapy, especially for solitary grade I MCTs. 7 In cases of incomplete resection ("dirty margins"), re-excision is recommended whenever possible. 89 If re-excision is considered impossible because of diffuse infiltration or massive tumour expansion, post-surgical radiation therapy is required, and in high-grade and/or metastasized MCT, radiation is usually combined with systemic anti-neoplastic therapy. 90, 91 In dogs with high-grade metastasized or unresectable MCTs, first-line treatment often consists of TKI therapy using masitinib (EU), toceranib (US, EU) or imatinib (Japan) or cytoreductive chemotherapeutics (eg, vinblastine, lomustine; often in combination with steroids). [38] [39] [40] More recently, the combination of toceranib with radiation therapy has been described to be an effective anti-neoplastic treatment approach for dogs with MCTs, including high-grade MCTs. 92 In case of primary or secondary resistance, different chemotherapy protocols using alternative cytoreductive drugs or combinations with TKI are prescribed. [93] [94] [95] [96] [97] [98] [99] However, although remissions can be achieved, responses are usually short-lived. [93] [94] [95] [96] [97] [98] [99] A summary of interventional treatment approaches in advanced SM in the human and canine system is depicted in Table 4 .
Concomitant treatment with H1-and H2-blockers is recommended to prevent mediator-related side effects in all patients. 100, 101 Whether the use of proton-pump inhibitors may improve the symptomatic treatment effect in canine MCT patients like in human SM patients remained to be evaluated in future clinical trials. Such comparative strategies require an interdisciplinary dialogue between human and veterinary medicine.
